PinCell
4.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Inaugural Michelin Guide New Zealand Reveals 1 Two Michelin Stars, 14 One Michelin Star And 35 Bib Gourmands1.7.2026 23:40:00 CEST | Press release
AUCKLAND, NZ / ACCESS Newswire / July 1, 2026 / The inaugural MICHELIN Guide New Zealand 2026 has recognised 110 restaurants across Auckland, Wellington, Christchurch and Queenstown, celebrating exceptional quality, creativity and a strong sense of place. After months of anonymous inspections, the MICHELIN Guide has awarded one restaurant in Queenstown, Essence, Two MICHELIN Stars. Fourteen restaurants have received One MICHELIN Star, 35 have been recognised with a Bib Gourmand for offering good food at great value, and a further 60 are included in the official MICHELIN Guide selection. Gwendal Poullennec, International Director of the MICHELIN Guide, said: "It is rare to award such a quantity of Stars in a country's inaugural launch, New Zealand's performance has been genuinely impressive. The destination presents more than a selection of outstanding restaurants; to our Inspectors, it revealed a contemporary culinary map shaped by unique terroir and a food culture in quiet harmony wit
Clockwork.io Launches The Industry's First Contractual Commitment to End GPU Waste in AI Training1.7.2026 17:00:00 CEST | Press release
"You Only Compute Once" (YOCO) guarantees to resolve 90% of AI training failures with no lost progress, or customers get credit PALO ALTO, CA / ACCESS Newswire / July 1, 2026 / Clockwork.io, pioneer of Software-Driven AI Fabrics™ and the company behind TorchPass AI fault tolerance, today announced the YOCO Guarantee - the industry's first contractual commitment to dramatically reduce the hidden, compounding cost of training failure in large-scale AI infrastructure. The announcement marks a turning point in how the AI industry measures infrastructure reliability - moving beyond uptime metrics designed for a previous era towards goals AI teams value most: whether the job finishes on time, without losing work. Under the YOCO (You Only Compute Once) Guarantee, Clockwork.io commits that at least 90% of training failures on supported TorchPass workloads will be resolved through live GPU migration, with no lost training progress, no checkpoint rollback, and no recompute. If Clockwork.io falls
Hydrosat Launches Data Discovery Platform, Unlocking 500 Million sq km of Satellite Imagery1.7.2026 15:00:00 CEST | Press release
New portal provides on-demand thermal imagery for critical resource monitoring, risk detection, and operational decision-making worldwide. WASHINGTON, D.C. AND LUXEMBOURG CITY, LUXEMBOURG / ACCESS Newswire / July 1, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced the launch of its new Discovery Portal, a centralized gateway for customers to access, explore, and leverage thermal imagery and analytics from space. The Discovery Portal enables organizations to access and evaluate thermal intelligence products powered by Hydrosat's flagship 30 m pixel-size Land Surface Temperature data set and growing constellation of thermal infrared satellites. Unlike traditional optical imagery, thermal imagery captures heat signatures from the Earth's surface, providing actionable insights across vast geographic areas, day or night, and often in conditions where conventional imaging is limited. With over 500 million sq km of imagery alre
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202630.6.2026 20:55:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2026 of $35,855,341 Total cash as at April 30, 2026 of $664,328 Working capital deficiency as at April 30, 2026 of $2,683,766 Shareholder's equity as at April 30, 2026 of $32,258,687 During the three-month period ended April 30, 2026, the Company incurred $57,783 in cost for exploration activities at the TBN project. During the quarter, the Company has been pursuing project financing alternatives while continuing to advance critical aspects of the project including progressing Advanced Exploration permitting discussions, and detailed planning for the next phase of exploration at E
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom